Insight Molecular Diagnostics (IMDX) Total Liabilities (2015 - 2026)

Insight Molecular Diagnostics has disclosed Total Liabilities across 12 years of filings, most recently posting $51.1 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $51.1 million, up 1.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $51.1 million (up 1.95% YoY), and the FY2025 annual result was $57.2 million, up 20.83% from the prior year.
• Total Liabilities came in at $51.1 million for Q1 2026 at Insight Molecular Diagnostics, down from $57.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $89.3 million in Q1 2022 to a low of $39.1 million in Q3 2023.
• The 5-year median for Total Liabilities is $52.0 million (2024), against an average of $55.9 million.
• Across the five-year window, Total Liabilities soared 293.82% in 2022 and slumped 55.95% in 2023, its largest moves.
• Insight Molecular Diagnostics' Total Liabilities stood at $60.5 million in 2022, then decreased by 18.51% to $49.3 million in 2023, then declined by 3.94% to $47.4 million in 2024, then increased by 20.83% to $57.2 million in 2025, then decreased by 10.66% to $51.1 million in 2026.
• The last three Total Liabilities figures came in at $51.1 million (Q1 2026), $57.2 million (Q4 2025), and $53.1 million (Q3 2025), per Business Quant data.